Company profile: Phenox
1.1 - Company Overview
Company description
- Provider of neuroradiological and radiological medical devices for treating acute ischemic stroke and intracranial aneurysms, including mechanical thrombectomy devices (pRESET), flow modulation devices (p64), bifurcation aneurysm implants (pCONUS), self-expanding stent systems (pEGASUS), and antithrombogenic HPC coatings that reduce thrombus formation by preventing platelet adhesion.
Products and services
- P64 Flow Modulation Device: A device engineered to treat complex intracranial aneurysms and dissections by modulating blood flow within the affected vessels
- PEGASUS Stent System: A self-expanding, open-cell stent system used for treating wide-neck aneurysms, dissections, and intracranial stenoses, available with antithrombogenic coating technology
- PRESET: A mechanical thrombectomy device used for the treatment of acute ischemic stroke by removing blood clots from large vessels in the brain.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phenox
Cingulate
HQ: United States
Website
- Description: Provider of precision timed-release therapeutics combining delivery technology with proven medications to deliver rapid-onset, once-daily, full-day efficacy. Portfolio includes ADHD treatments CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), and CTx-2103 (buspirone HCl) for anxiety under development, powered by its Precision Timed Release (PTR) platform enabling predefined release times.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cingulate company profile →
Silo Pharma
HQ: United States
Website
- Description: Provider of developmental-stage biopharmaceutical research merging traditional therapeutics with psychedelic research, developing: SPC-15, an intranasal 5-HT(4) receptor agonist for PTSD and stress-induced anxiety; SP-26, a ketamine-based injectable dissolvable implant for chronic pain and fibromyalgia; SPC-14, an intranasal compound for Alzheimer’s targeting NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms; and SPU-16, a CNS homing peptide for MS and other neuroinflammatory pathologies, improving delivery and reducing toxicity of therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silo Pharma company profile →
Lexeo Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy candidates for genetically defined cardiovascular and CNS diseases, including LX2006 for cardiac Friedreich’s ataxia (frataxin), LX2020 for arrhythmogenic cardiomyopathy (PKP2), LX2021 for desmoplakin cardiomyopathy and certain forms of dilated cardiomyopathy (connexin 43), LX2022 for hypertrophic cardiomyopathy (TNNI3), and CNS APOE2 programs for APOE4 homozygous Alzheimer’s (LX1001, LX1020).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexeo Therapeutics company profile →
ANS Medical
HQ: United States
Website
- Description: Provider of neuromodulation devices, engaged in their design, development, and manufacture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ANS Medical company profile →
Aequus Pharmaceuticals
HQ: Canada
Website
- Description: Provider of ophthalmology and transplant treatments and devices, offering Tacrolimus IR for organ rejection prophylaxis and refractory rejection; Vistitan and Zimed PF (bimatoprost 0.03%) to reduce intraocular pressure; Evolve preservative-free lubricating eye drops; the Zepto Capsulotomy System for cataract surgery; and REV-0100, a potential therapy for Stargardt disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aequus Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phenox
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phenox
2.2 - Growth funds investing in similar companies to Phenox
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phenox
4.2 - Public trading comparable groups for Phenox
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →